Sarepta / Eisai Andover MA

Eisai Inc., the U.S. subsidiary of Tokyo-based Eisai Co., Ltd., retained PharmaBioSource Realty, LLC as its exclusive real estate broker to market and sell a 60,000-square-foot high-potency small-molecule API development and manufacturing facility in Andover, Massachusetts. The divestiture was part of Eisai’s manufacturing network consolidation program. Located on 26 acres approximately 30 miles from Boston, the site offered a strategic buyer the opportunity to acquire a world-class high-potency API asset at a discount to replacement cost, with a substantial reduction in time to market. The facility’s specialized high-potency capability and proximity to the Boston biotech cluster narrowed the buyer universe to pharma and biotech operators where industry-specific network access — not a broad marketing process — determined the outcome.

PharmaBioSource Realty engaged the pharmaceutical and biotech industry to market and sell the Andover facility to a strategic acquirer. We drew on real estate and technical expertise and our extensive contacts within the pharmaceutical industry to identify qualified potential buyers for the site.

Services provided by the PharmaBioSource Realty team:

• Facility and equipment assessments
• Prep for sale
• Creation of introductory project teaser
• Target identification and marketing
• Support in developing a data room
• Managed confidentiality agreements
• Hosted site visits and meetings with Eisai and buyer management
• Supported buyer due diligence
• Contract documents
• Deal structure and negotiations
• Closing

PharmaBioSource Realty identified Sarepta Therapeutics — a Cambridge, Massachusetts-based commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics for rare neuromuscular diseases — as the acquirer. The $25M transaction closed in just seven months from initial engagement.